Drug intelligence / Profile preview

metoprolol + hydrochlorothiazide

Development stage
Unknown
Lead developer
AstraZeneca
Modality
Small Molecules
Administration
Oral
01

Overview

Metoprolol + hydrochlorothiazide is a fixed-dose combination of two antihypertensive agents: the beta-blocker metoprolol (typically as the tartrate salt) and the thiazide diuretic hydrochlorothiazide. This combination is used to treat high blood pressure (hypertension), thereby reducing cardiovascular risk such as stroke, heart attack, or kidney failure. Metoprolol works by selectively blocking beta-1 adrenergic receptors in the heart, leading to decreased heart rate and cardiac output. Hydrochlorothiazide acts on the distal renal tubules to inhibit sodium reabsorption, increasing excretion of sodium and water, which lowers blood volume and thus blood pressure. The combination provides additive antihypertensive effects through complementary mechanisms—cardiac modulation by beta-blockade and reduction of plasma volume via diuresis[1][2][3][4][5].

Brand names
Lopressor HCTDutoprol
Other names
hydrochlorothiazide and metoprololmetoprolol/hydrochlorothiazidemetoprolol tartrate and hydrochlorothiazide
02

Targets

ADRB1 (β1)SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)

Beyond the preview

Go deeper on metoprolol + hydrochlorothiazide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on metoprolol + hydrochlorothiazide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call